PET/CT as a Diagnostic Test for Polymyalgia Rheumatica

Not Applicable

Recruiting

• Conditions: Polymyalgia rheumatica; Inflammatory and Immune System - Other inflammatory or immune system disorders; Musculoskeletal - Other muscular and skeletal disorders

• Registration Number: ACTRN12623000290695
• Lead Sponsor: Rheumatology Clinical Trials, Austin Health

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-03-17
• Last Update Posted: 4 March 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Suspected new diagnosis of PMR as determined by age at symptom onset greater than or equal to 50 years, bilateral shoulder aching, and elevated CRP and/or ESR (in line with 2012 EULAR/ACR Classification Criteria).

Exclusion Criteria

- Inability to provide informed consent.
- Patients with symptoms suggestive of giant cell arteritis (headache, jaw claudication, scalp tenderness and/or visual disturbance).
- Patients with active infection.
- Patients with recent malignancy.
- Patients with established inflammatory rheumatic diseases (e.g. RA).
- Patients with uncontrolled diabetes (due to inability to accurately interpret 18F-FDG uptake).
- Patients who have been treated with glucocorticoids for greater than 7 days prior to screening, a single dose of prednisolone greater than or equal to 30mg/day and concomitant DMARD therapy.

Study & Design

• Study Type: Interventional
• Study Design: Not specified